BioCentury | Nov 11, 2019
Clinical News

Nov. 11 SITC Roundup: Celyad's first clinical data for allogeneic CAR Ts, plus Vaccibody and Nektar

...ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Nektar Therapeutics Vaccibody A/S Celyad S.A. Interleukin-2 (IL-2) receptor beta chain (IL2RB) (CD122) allogeneic...
BioCentury | Oct 4, 2019
Finance

Biotech down again in 3Q19

...N.V. Nektar Therapeutics Shenzhen Chipscreen Biosciences Ltd. Clovis Oncology Inc. Opthea Ltd. Transgene S.A. Neurotrope Inc. Deciphera Pharmaceuticals Inc. Gilead Sciences Inc. Bristol-Myers Squibb Co. Interleukin-2 (IL-2) receptor beta chain (IL2RB) (CD122)...
BioCentury | Sep 26, 2019
Clinical News

Nektar falls on TNBC data for doublet, but considering moving ahead with a triple combo

...ONO-4538 (Compound #), MDX-1106 (Compound #), BMS-936558 (Compound #), nivolumab (Generic), Opdivo (Other) Nektar Therapeutics Bristol-Myers Squibb Co. Interleukin-2 (IL-2) receptor beta chain (IL2RB) (CD122) Programmed...
BioCentury | Jul 18, 2019
Emerging Company Profile

Neoleukin emerges with a de novo approach to improving biologics

...Writer Proleukin, aldesleukin (Macrolin) Neoleukin Therapeutics Inc. Novartis AG Seattle Genetics Inc. University of Washington Interleukin-2 (IL-2) Interleukin-2 (IL-2) receptor alpha chain (CD25) Interleukin-2 (IL-2) receptor beta chain (IL2RB) (CD122) Interleukin-2...
BioCentury | Jun 3, 2019
Clinical News

A tale of two ASCOs: Nektar gains on durability of complete response rate for NKTR-214 combo

...PD-1 (PDCD1; CD279) - Programmed cell death 1 Chris Lieu, Staff Writer NKTR-214 American Society of Clinical Oncology ASCO Nektar Therapeutics Interleukin-2 (IL-2) receptor beta chain (IL2RB) (CD122) bempegaldesleukin...
Items per page:
1 - 5 of 5